Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial

Bulluck, Heerajnarain ORCID: https://orcid.org/0000-0002-1985-1783, Fröhlich, Georg M., Nicholas, Jennifer M., Mohdnazri, Shah, Gamma, Reto, Davies, John, Sirker, Alex, Mathur, Anthony, Blackman, Daniel, Garg, Pankaj ORCID: https://orcid.org/0000-0002-5483-169X, Moon, James C., Greenwood, John P. and Hausenloy, Derek J. (2019) Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial. American Heart Journal, 211. pp. 60-67. ISSN 0002-8703

Preview

PDF (Published_Version) - Published Version Available under License Creative Commons Attribution. Download (558kB) | Preview

Abstract

Mineralocorticoid receptor antagonist (MRA) therapy has been shown to prevent adverse left ventricular (LV) remodeling in ST-segment elevation myocardial infarction (STEMI) patients with heart failure. Whether initiating MRA therapy prior to primary percutaneous coronary intervention (PPCI) accrues additional benefit of reducing myocardial infarct size and preventing adverse LV remodeling is not known. We aimed to investigate whether MRA therapy initiated prior to reperfusion reduces myocardial infarct (MI) size and prevents adverse LV remodeling in STEMI patients.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Related URLs:	https://linkinghub.elsevier.com/retrieve...
Depositing User:	LivePure Connector
Date Deposited:	18 Nov 2021 01:58
Last Modified:	19 Oct 2023 03:09
URI:	https://ueaeprints.uea.ac.uk/id/eprint/82196
DOI:	10.1016/j.ahj.2019.02.005

Downloads

Actions (login required)

View Item